Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683888 | 0.88 | SMN1; SMN2 (0.51) | MAOBALDH1A1ADORA2AADORA2BTP53 | |
| Hydrochloric Acid SCHEMBL11381649 | 0.87 | SMN1; SMN2 (0.50) | MAOBALDH1A1ADORA2AADORA2BTP53 | |
| SCHEMBL684271 | 0.86 | TSHR (0.54) | MAOBALDH1A1ADORA2AADORA2BMAOA | |
| SCHEMBL683962 | 0.85 | ADORA2B (0.62) | MAOBALDH1A1ADORA2AADORA2B | |
| Hydrochloric Acid SCHEMBL11384998 | 0.85 | TSHR (0.53) | MAOBALDH1A1ADORA2AADORA2BMAOA | |
| Hydrochloric Acid SCHEMBL11388923 | 0.84 | ADORA2B (0.61) | MAOBALDH1A1ADORA2AADORA2B | |
| SCHEMBL683542 | 0.84 | NCOA3 (0.54) | MAOBALDH1A1ADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL11381068 | 0.83 | NCOA3 (0.53) | MAOBALDH1A1ADORA2AADORA2BADORA3 | |
| SCHEMBL682759 | 0.81 | SMN1; SMN2 (0.53) | MAOBALDH1A1ADORA2AADORA2BADORA1 | |
| SCHEMBL7034529 | 0.81 | ADORA2B (0.55) | MAOBKDM4EALDH1A1ADORA2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | MAOB 808/4885KDM4E 2527/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.